JPRN-jRCTs061180095招募中1 期
Phase I/II study of S-1, docetaxel, oxaliplatin combination chemotherapy in patients with HER2-negative unresectable metastatic gastric cancer - Phase I/II study of DOS
Takayama Tetsuji0 个研究点目标入组 30 人开始时间: 2019年3月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1)Written informed consent.
- •2)Histologicaly (cytologically) proven gastric cancer.
- •3)HER2 negative method
- •4)Unresectable gastric cancer.
- •5)To have evaluable lesions.
- •6)No prior chemotherapy or no influence of prior therapy.
- •7)Tolerable function of bone marrow, liver, and kidney.
- •8)PS 0 - 1.
- •9)Expected survival for three months.
- •10)Possible oral intake.
排除标准
- •1)History of hypersensitivity to DCS.
- •2)Contraindication to DTX, Oxaliplatin, S-1.
- •3)Infectious disease.
- •4)Severe complication.
- •5)Brain metastasis with clinical symptoms.
- •6)Watery diarrhea.
- •7)Active double cancer.
- •9)Persons to be pregnant or to make pregnant.
研究者
相似试验
招募中
不适用
Phase I/II study of S-1, docetaxel, oxaliplatin combination chemotherapy (DOS) in patients with HER2-negative unresectable metastatic gastric cancergastric cancerJPRN-UMIN000015849Department of Gastroenterology and Oncology59
已完成
1 期
Phase 1 study of Docetaxel and Oxaliplatin and TS-1 for unresectable / recurrent gastric cancer (KOGC-06)unresectable / recurrent gastric cancerJPRN-UMIN000015723Keio University School of Medicine, Department of Surgery5
已完成
1 期
Phase I/II Study of S-1, Cisplatin and Docetaxel in Patients with Advanced Gastric Canceruntreated advanced or recurrent gastric cancerJPRN-UMIN000000484Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama40
已完成
2 期
Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric CancerStomach NeoplasmsNCT00525005Hallym University Medical Center44
已完成
1 期
Phase I study of Docetaxel, Cisplatin and S-1 in patients with advanced or recurrent gastric cancerGastric cancerJPRN-UMIN000000978Shizuoka Cancer Center18